EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiic

EGFR Non-Small Cell Lung Cancer Pipeline constitutes 25+ key companies continuously working towards developing 30+ EGFR Non-Small Cell Lung Cancer treatment therapies, analyzes DelveInsight.

EGFR Non-Small Cell Lung Cancer Overview:

EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) is a subtype of lung cancer caused by mutations in the EGFR gene, leading to uncontrolled cell growth. It accounts for 10-15% of NSCLC cases in Western populations and 30-50% in Asian populations, predominantly affecting non-smokers, women, and adenocarcinoma patients.

Early symptoms are often mild, including cough, chest pain, shortness of breath, and weight loss, making early detection difficult. As the disease advances, metastasis may cause bone pain, headaches, or neurological issues.

The exact causes remain unclear, but genetic predisposition and environmental factors like secondhand smoke, air pollution, and radon exposure may contribute. Many cases occur in non-smokers, indicating alternative cancer pathways.

Diagnosis involves imaging tests (X-rays, CT, PET scans) and biopsies for molecular testing. Liquid biopsy, analyzing circulating tumor DNA, is emerging as a non-invasive diagnostic tool.

Treatment primarily includes EGFR tyrosine kinase inhibitors (TKIs) that block the mutated receptor. First- and second-generation TKIs (erlotinib, gefitinib, afatinib) are available, but osimertinib is preferred for its ability to target resistance mutations and brain metastases. If TKIs fail, chemotherapy, immunotherapy, or combination therapies may be used. Research continues to improve treatment options.

Request for a detailed insights report on EGFR Non-Small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"EGFR Non-Small Cell Lung Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the EGFR Non-Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report

DelveInsight's EGFR Non-Small Cell Lung Cancer pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR Non-Small Cell Lung Cancer treatment.
Key EGFR Non-Small Cell Lung Cancer companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics, and others are evaluating new drugs for EGFR Non-Small Cell Lung Cancer to improve the treatment landscape.
Promising EGFR Non-Small Cell Lung Cancer pipeline therapies in various stages of development include CLN-081, BPI-361175, G1T38, JANX008, and others.

Recent breakthroughs in the EGFR Non-Small Cell Lung Cancer Pipeline Segment:

In October 2024, a global clinical trial demonstrated that a combination of amivantamab and lazertinib significantly prolonged progression-free survival in patients with advanced NSCLC compared to the current standard treatment, osimertinib. The combination extended disease progression time by an average of 23.7 months, compared to 16.6 months with osimertinib.

EGFR Non-Small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the EGFR Non-Small Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR Non-Small Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the EGFR Non-Small Cell Lung Cancer market.

Download our free sample page report on EGFR Non-Small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

EGFR Non-Small Cell Lung Cancer Emerging Drugs

CLN-081: Cullinan Oncology
BPI-361175: Betta Pharmaceuticals
G1T38: G1 Therapeutics
JANX008: Janux Therapeutics

EGFR Non-Small Cell Lung Cancer Companies

Approximately 25 or more key companies are engaged in developing therapies for EGFR-positive Non-Small Cell Lung Cancer (EGFR+ NSCLC). Among them, Cullinan Oncology has a drug candidate in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging EGFR Non-Small Cell Lung Cancer Therapies and Key Companies: EGFR Non-Small Cell Lung Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

EGFR Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment
• EGFR Non-Small Cell Lung Cancer Assessment by Product Type
• EGFR Non-Small Cell Lung Cancer By Stage
• EGFR Non-Small Cell Lung Cancer Assessment by Route of Administration
• EGFR Non-Small Cell Lung Cancer Assessment by Molecule Type

Download EGFR Non-Small Cell Lung Cancer Sample report to know in detail about the EGFR Non-Small Cell Lung Cancer treatment market @ EGFR Non-Small Cell Lung Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. EGFR Non-Small Cell Lung Cancer Current Treatment Patterns
4. EGFR Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. EGFR Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. EGFR Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. EGFR Non-Small Cell Lung Cancer Discontinued Products
13. EGFR Non-Small Cell Lung Cancer Product Profiles
14. EGFR Non-Small Cell Lung Cancer Key Companies
15. EGFR Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. EGFR Non-Small Cell Lung Cancer Unmet Needs
18. EGFR Non-Small Cell Lung Cancer Future Perspectives
19. EGFR Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the EGFR Non-Small Cell Lung Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.